catalyst

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve — primary completion

as of 2026-07-01
Monitor thisAsk about this
at a glance
2013-11 · Actual — This event happened.
Synthesized from structured facts only — each point cited above.

Event

What
Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve — primary completion
Type
Trial Readout
Date
2013-11
Date type
ACTUAL
Phase
Phase 2
This event happened.
relationships
The graph out of here
trial
Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia
trial